ABSTRACT
This study investigates the impact of progesterone resistance on endometrial receptivity and evaluates the efficacy of pituitary downregulation combined with hormone replacement therapy (HRT) in improving pregnancy outcomes following frozen embryo transfer (FET). A retrospective analysis was conducted on 147 patients with recurrent implantation failure (RIF) who underwent secretory-phase endometrial biopsy and subsequent FET treatments at the Reproductive Center of the First Affiliated Hospital of Guangxi Medical University between April 2019 and May 2022. Based on biopsy results and endometrial preparations, patients were categorized into four groups: secretory phase + non-downregulated protocol group (n=29), secretory phase + GnRH-a + HRT Protocol group (n=20), proliferative phase + non-downregulated protocol group (n=59), proliferative Phase + GnRH-a + HRT Protocol group (n=39). Endometrial preparation regimens and pregnancy outcomes during the first FET cycle after biopsy were compared. The results showed that there was no statistical difference in the outcome of assisted pregnancy between the different endometrial preparation protocols in the four groups. These findings suggest that the prioritization of down-regulation protocols may not be essential for FET in patients with RIF, even when endometrial biopsy during the implantation window reveals proliferative-phase characteristics.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Ethics All the authurs ensured that we had discussed whether all data were fully anonymized before we accessed them. The need for consent was waived by the ethics committee and the information is included. Committee of the First Affiliated Hospital of Guangxi Medical University and Ethics Committee of the Guigang People's Hospital (approval number: 2024-E0850, ELW-2024-029-01). All authors had not access to information that could identify individual participants during or after data collection.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Footnotes
↵a Yuxing Luo and Changshuang Cen are co-first authors.
INSTITUTIONAL EMAIL: ydkyb2013{at}163.com.
Data Availability
Data cannot be shared publicly because of the protection of patient data privacy. Data are available from the Ethics Committee of the First Affiliated Hospital of Guangxi Medical University and Ethics Committee of the Guigang People's Hospital for researchers who meet the criteria for access to confidential data.
